[go: up one dir, main page]

MX2016002375A - Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxololona o sus análogos. - Google Patents

Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxololona o sus análogos.

Info

Publication number
MX2016002375A
MX2016002375A MX2016002375A MX2016002375A MX2016002375A MX 2016002375 A MX2016002375 A MX 2016002375A MX 2016002375 A MX2016002375 A MX 2016002375A MX 2016002375 A MX2016002375 A MX 2016002375A MX 2016002375 A MX2016002375 A MX 2016002375A
Authority
MX
Mexico
Prior art keywords
methods
dysfunction
bardoxololona
endotelial
metil
Prior art date
Application number
MX2016002375A
Other languages
English (en)
Other versions
MX380589B (es
Inventor
Pei- Heng Chin Melanie
J Meyer Colin
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2016002375A publication Critical patent/MX2016002375A/es
Publication of MX380589B publication Critical patent/MX380589B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a métodos para tratar y evitar disfunción endotelial y trastornos relacionados, incluyendo, por ejemplo, hipertensión arterial pulmonar, utilizando metil bardoxolona o sus análogos.
MX2016002375A 2013-08-23 2014-08-22 Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxolona o sus análogos. MX380589B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361869527P 2013-08-23 2013-08-23
PCT/US2014/052382 WO2015027206A1 (en) 2013-08-23 2014-08-22 Methods of treating and preventing endothelial dysfunction using bardoxololone methyl or analogs thereof

Publications (2)

Publication Number Publication Date
MX2016002375A true MX2016002375A (es) 2016-12-20
MX380589B MX380589B (es) 2025-03-12

Family

ID=51794949

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002375A MX380589B (es) 2013-08-23 2014-08-22 Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxolona o sus análogos.
MX2021002897A MX2021002897A (es) 2013-08-23 2016-02-23 Metodos de tratamiento y prevencion de la disfuncion endotelial utilizando metil bardoxolona o sus analogos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002897A MX2021002897A (es) 2013-08-23 2016-02-23 Metodos de tratamiento y prevencion de la disfuncion endotelial utilizando metil bardoxolona o sus analogos.

Country Status (18)

Country Link
US (3) US20150080465A1 (es)
EP (1) EP3035937B1 (es)
JP (3) JP6564372B2 (es)
KR (1) KR102322057B1 (es)
CN (2) CN112870202A (es)
AU (2) AU2014308600B2 (es)
BR (1) BR112016003454B1 (es)
CA (1) CA2921386A1 (es)
CL (1) CL2016000405A1 (es)
EA (1) EA201690456A1 (es)
IL (3) IL285832B2 (es)
MX (2) MX380589B (es)
MY (2) MY205497A (es)
NZ (4) NZ630951A (es)
PH (1) PH12016500358B1 (es)
SG (2) SG10201906113RA (es)
TW (2) TWI716341B (es)
WO (1) WO2015027206A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104739841B (zh) 2008-01-11 2018-06-01 里亚塔医药公司 合成三萜类化合物及用以治病之方法
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
ME02973B (me) 2010-12-17 2018-07-20 Reata Pharmaceuticals Inc Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije
PT3444261T (pt) 2012-04-27 2021-03-12 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de metil bardoxolona, formas polimorfas e métodos de uso dos mesmos
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI630212B (zh) 2012-09-10 2018-07-21 瑞塔醫藥有限責任公司 丁香油素（ｏｌｅａｎｏｌｉｃ ａｃｉｄ）之ｃ１７－烷二基與烯二基衍生物及其使用方法
UY39092A (es) 2013-04-24 2021-03-26 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
CA2921386A1 (en) * 2013-08-23 2015-02-26 Reata Pharmaceuticals, Inc. Methods of treating and preventing renal disease using bardoxolone methyl or analogs thereof
WO2016130927A1 (en) 2015-02-12 2016-08-18 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant iflammation modulators
EP3310786B1 (en) 2015-06-16 2021-03-03 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
AU2016326704B2 (en) 2015-09-23 2021-01-28 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2018200692A1 (en) * 2017-04-26 2018-11-01 The Trustees Of The University Of Pennsylvania Methods and systems for virtual and augmented reality training for responding to emergency conditions
CA3103726A1 (en) 2018-06-15 2019-12-19 Reata Pharmaceuticals, Inc. Pyrazole and imidazole compounds for inhibition of il-17 and rorgamma
WO2019246461A1 (en) 2018-06-20 2019-12-26 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
CA3114354A1 (en) * 2018-09-28 2020-04-02 Sichuan Haisco Pharmaceutical Co., Ltd. Terpinoid derivatives and uses thereof
WO2020080482A1 (ja) * 2018-10-17 2020-04-23 株式会社 資生堂 血液中のシスタチンｃ量に基づく腎機能検査結果の妥当性を検定する方法
AU2020316351A1 (en) * 2019-07-19 2022-02-17 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
EP4067367B1 (en) * 2019-11-27 2025-05-28 Lunan Pharmaceutical Group Corporation Oleanane cinnamamide derivative, preparation method therefor, and use thereof
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
JP7565912B2 (ja) * 2019-12-23 2024-10-11 東レ株式会社 透析移行又は腎死の抑制のための薬剤
WO2021202720A1 (en) * 2020-04-01 2021-10-07 Fronthera U.S. Pharmaceuticals Llc Use of triterpenoid nrf2 inhibitors
CA3177913A1 (en) * 2020-05-09 2021-11-18 Deborah FERGUSON Methods of treating covid-19 using bardoxolone methyl or analogs thereof
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
WO2022126129A1 (en) 2020-12-11 2022-06-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids for use in therapy
US12064409B2 (en) * 2021-06-22 2024-08-20 Vanderbilt University Action of L-citrulline to prevent or treat endothelial dysfunction
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
CN116509874A (zh) * 2023-02-01 2023-08-01 潍坊医学院附属医院 甲基巴多索隆在制备改善病毒性心肌炎或病毒性心肌损伤的药物中的用途
CN117964678A (zh) * 2024-01-29 2024-05-03 烟台大学 C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
WO1992018866A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
GB9212302D0 (en) 1992-06-10 1992-07-22 Applied Research Systems Method for improving measurement precision in evanescent wave optical biosensor assays
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
EP1465615B1 (en) 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
US20050239867A1 (en) * 2004-04-23 2005-10-27 Zeldis Jerome B Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
WO2008137991A1 (en) 2007-05-08 2008-11-13 Abbott Laboratories Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
CN104739841B (zh) * 2008-01-11 2018-06-01 里亚塔医药公司 合成三萜类化合物及用以治病之方法
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
TWI442925B (zh) 2008-04-18 2014-07-01 Reata Pharmaceuticals Inc 抗氧化性發炎調節劑：ｃ－環飽和之齊墩果酸衍生物
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
JP5775464B2 (ja) 2009-02-13 2015-09-09 リアタ ファーマシューティカルズ，インク 非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物
MY163031A (en) * 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
CA2921386A1 (en) * 2013-08-23 2015-02-26 Reata Pharmaceuticals, Inc. Methods of treating and preventing renal disease using bardoxolone methyl or analogs thereof
CA3177913A1 (en) * 2020-05-09 2021-11-18 Deborah FERGUSON Methods of treating covid-19 using bardoxolone methyl or analogs thereof

Also Published As

Publication number Publication date
SG10201906113RA (en) 2019-08-27
MX2021002897A (es) 2021-06-08
PH12016500358B1 (en) 2023-08-16
AU2014308600A1 (en) 2016-03-03
MX380589B (es) 2025-03-12
AU2014308600B2 (en) 2020-03-05
EP3035937A1 (en) 2016-06-29
IL272242A (en) 2020-02-27
EP3035937B1 (en) 2025-12-31
NZ630951A (en) 2018-09-28
JP2019048873A (ja) 2019-03-28
JP6526306B2 (ja) 2019-06-05
TW202026003A (zh) 2020-07-16
WO2015027206A1 (en) 2015-02-26
KR102322057B1 (ko) 2021-11-05
PH12016500358A1 (en) 2016-05-16
EA201690456A1 (ru) 2016-06-30
IL285832A (en) 2021-09-30
JP6701407B2 (ja) 2020-05-27
NZ744036A (en) 2020-09-25
CA2921386A1 (en) 2015-02-26
US20150080465A1 (en) 2015-03-19
SG11201601202WA (en) 2016-03-30
KR20160061994A (ko) 2016-06-01
TWI717026B (zh) 2021-01-21
IL244171A0 (en) 2016-04-21
TWI716341B (zh) 2021-01-21
WO2015027206A8 (en) 2015-06-11
CN105517554B (zh) 2021-01-15
IL244171B (en) 2020-02-27
NZ774222A (en) 2023-01-27
BR112016003454A2 (pt) 2017-08-01
CN112870202A (zh) 2021-06-01
HK1223015A1 (zh) 2017-07-21
NZ756256A (en) 2021-07-30
CN105517554A (zh) 2016-04-20
US20190091194A1 (en) 2019-03-28
JP2019131599A (ja) 2019-08-08
IL285832B1 (en) 2023-09-01
IL272242B (en) 2021-09-30
IL285832B2 (en) 2024-01-01
AU2020203510A1 (en) 2020-06-18
MY205497A (en) 2024-10-23
US20240115542A1 (en) 2024-04-11
MY198522A (en) 2023-09-04
TW201542211A (zh) 2015-11-16
JP6564372B2 (ja) 2019-08-21
CL2016000405A1 (es) 2017-02-24
JP2016528300A (ja) 2016-09-15
AU2020203510B2 (en) 2023-05-11
BR112016003454B1 (pt) 2023-02-14

Similar Documents

Publication Publication Date Title
MX2016002375A (es) Métodos de tratamiento y prevencion de la disfunción endotelial utilizando metil bardoxololona o sus análogos.
IL285151A (en) Methods of treating fgf21-associated disorders
MA46180A (fr) Analogues de l'amyline
IL257379A (en) Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
EP3558188A4 (en) COMPOSED Wound Bandage With Charcoal
LT3122752T (lt) 4'-pakeistųjų nukleozidų dariniai kaip živ atvirkštinės transkriptazės inhibitoriai
PL3265053T3 (pl) Sposoby leczenia skóry
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MA42036A (fr) Analogues nucléosidiques 5'-substitués
PL3145522T3 (pl) Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
HUE056287T2 (hu) Pancreatitis kezelése
PL4023222T3 (pl) Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q
PT3572410T (pt) Análogos dioxolano de uridina para o tratamento de cancro
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
IL262803B (en) Methods of treating circadian rhythm sleep disorders
HUE042763T2 (hu) Módosított szerpinek vérzési rendellenességek kezelésére
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
EP3592377A4 (en) TISSUE KALLICREIN DOSAGE FORMS 1
MX2016014166A (es) Compuestos de triaminopirimidina utiles para evitar o tratar la malaria.
EA201791689A1 (ru) Новые композиции и способы лечения и/или предупреждения хронического обструктивного заболевания легких
LT3273957T (lt) Biotinas, skirtas demielinizuojančių neuropatijų gydymui
DK3585327T3 (da) System til behandling af søvnforstyrret åndedræt